Targeting of EGFR with 99mTc-Cetuximab in our setting resulted in a relatively low overall A431 tumour uptake of 6.5% ID/g compared to tumour uptakes of up to 20% ID/g observed by others20, 21. This evidence concerns the gene EGFR and neoplasm.